Eupraxia Pharmac Stock Price, News & Analysis

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced the pricing of its public offering of 12,727,273 common shares at US$5.50 per share, aiming to raise approximately US$70 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase up to an additional 1,909,090 shares under the same terms.

The offering, expected to close on September 24, 2025, is being managed by Cantor and LifeSci Capital as joint book-running managers, with Bloom Burton as co-manager. The proceeds will fund pipeline advancement, clinical trials, regulatory submissions, commercial preparation, and manufacturing scale-up activities. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced a proposed public offering of common shares. The company has filed a preliminary prospectus supplement to its base shelf prospectus for the offering, which includes a 30-day option for underwriters to purchase up to an additional 15% of shares.

The offering will be jointly managed by Cantor and LifeSci Capital as book-running managers, with Bloom Burton acting as co-manager. The proceeds will primarily fund the company's product pipeline development, including ongoing clinical trials, regulatory submissions, and commercial preparation. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.

The final terms and size of the offering will be determined at pricing, with completion subject to customary conditions including TSX and Nasdaq listing approvals.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced positive 1-year clinical results from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The trial demonstrated that 67% of patients in Cohort 5 (48mg dose) maintained clinical remission after 12 months.

Key findings include significant tissue health improvements, with patients treated with 4mg per injection showing 47% improvement in grade and 44% in stage at week 36. The drug maintained steady plasma levels through 52 weeks, below typical asthma inhaler levels. Importantly, no serious adverse events or oral/gastrointestinal candidiasis were reported.

The company believes EP-104GI could potentially offer a revolutionary once-yearly treatment option, administered during routine annual endoscopy procedures, presenting a significant advantage over current daily oral steroids or weekly biologics.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q2 2025 financial results and provided updates on its EP-104GI clinical program for Eosinophilic Esophagitis (EoE). The company has initiated the Phase 2b placebo-controlled portion of the RESOLVE trial, with topline data expected in H2 2026. The trial will enroll a minimum of 60 patients across 25 global sites.

Key financial metrics include a net loss of $8.7 million for Q2 2025, compared to $6.1 million in Q2 2024. Cash position stands at $19.8 million as of June 30, 2025, expected to fund operations into Q3 2026. Recent Phase 1b/2a data showed sustained positive treatment outcomes after nine months of therapy, with no serious adverse events reported.

Eupraxia Pharmaceuticals (NASDAQ:EPRX), a clinical-stage biotech company, has announced its participation in four upcoming investor conferences in August and September 2025. The company, which specializes in DiffuSphere™ technology for optimized local drug delivery, will present at the Canaccord Growth Conference (August 12-14), Citi Biopharma Conference (September 2-3), Cantor Global Healthcare Conference (September 3-5), and H.C. Wainwright Global Investment Conference (September 8-10).

The presentations will take place in Boston and New York, with scheduled times at 9:30am ET on August 13 at Canaccord and 9:10am ET on September 5 at Cantor.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has initiated the Phase 2b placebo-controlled portion of its RESOLVE clinical trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). The study will enroll minimum 60 patients across 25 global sites, evaluating two active doses against placebo over 12 months.

The trial's first active dose of 120 mg was selected based on encouraging early data from cohort 8, showing the largest decline in Peak Eosinophil Count and lowest EoEHSS scores at 4 weeks. The study will assess tissue health, symptom scores, and safety, with placebo patients eligible to receive EP-104GI after six months. Topline data is expected by Q3 2026, with additional Phase 2a data releases planned for September and November 2025.

Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) held its Annual General and Special Meeting on June 2, 2025, where shareholders approved all proposed items. All six board nominees were successfully elected with high approval rates, led by James A. Helliwell and Joseph Freedman with 99.997% votes in favor. Shareholders also approved the appointment of KPMG LLP as auditors, the 2025 Omnibus Incentive Plan, and the re-pricing of certain non-executive employee stock options. Eupraxia is advancing its DiffuSphere™ technology platform, designed for targeted drug delivery with extended-release capabilities. The company has two key clinical programs: EP-104GI in Phase 1b/2a for EoE treatment and EP-104IAR, which recently completed a successful Phase 2b trial for knee osteoarthritis pain, meeting its primary endpoint and three secondary endpoints.

Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) has announced a virtual Key Opinion Leader (KOL) event scheduled for May 9, 2025, at 9:00 AM ET. The event will feature Dr. Evan Dellon from the University of North Carolina, Chapel Hill, alongside company management to discuss additional clinical data from the Phase 1b/2a RESOLVE Study of EP-104GI for treating eosinophilic esophagitis (EoE).

Dr. Dellon will join CEO Dr. James Helliwell to explore the unmet needs in EoE treatment, current treatment landscape, and how the RESOLVE study's safety and efficacy data suggests EP-104GI's potential to become a new standard of care. The event will conclude with a Q&A session.

Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported its Q1 2025 financial results and provided updates on its EP-104GI clinical trial for Eosinophilic Esophagitis (EoE). The company highlighted positive nine-month data from the Phase 1b/2a RESOLVE trial, showing sustained treatment outcomes with a single 48mg dose. Financial results showed a net loss of $6.8 million compared to $6.2 million in Q1 2024. The company maintains a strong cash position of $27.5 million as of March 31, 2025, with runway extending to Q3 2026. Key developments include the appointment of Alex Rothwell as CFO and continued positive trial results with no serious adverse events reported. The company is monitoring potential impacts of proposed U.S.-Canada tariffs on its operations.